CHAC2 promotes lung adenocarcinoma by regulating ROS-mediated MAPK pathway activation

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Oxidative stress, an imbalance between reactive oxidative species (ROS) and antioxidants, is crucial in tumorigenesis.
• Glutathione (GSH) is a key antioxidant that neutralizes ROS, protecting cells from oxidative damage.
• The specific role of CHAC2, an enzyme involved in GSH regulation, in lung adenocarcinoma pathogenesis was previously unknown.

Purpose of the Study:

• To investigate the expression and function of CHAC2 in lung adenocarcinoma.
• To elucidate the underlying molecular mechanisms by which CHAC2 influences lung adenocarcinoma progression.

Main Methods:

• RNA sequencing and immunohistochemistry (IHC) to assess CHAC2 expression in lung adenocarcinoma tissues.
• In vitro (cell culture) and in vivo (xenograft mouse models) assays to evaluate CHAC2's impact on cell proliferation.
• Western blot, IHC, and flow cytometry to analyze ROS levels, GSH levels, and pathway activation.

Main Results:

• CHAC2 expression was significantly upregulated in lung adenocarcinoma tissues compared to normal tissues.
• Overexpression of CHAC2 enhanced lung adenocarcinoma cell proliferation both in vitro and in vivo.
• CHAC2 promoted lung adenocarcinoma progression by reducing GSH levels, increasing ROS, and subsequently activating the MAPK signaling pathway.

Conclusions:

• CHAC2 plays a significant role in promoting lung adenocarcinoma cell growth and progression.
• The mechanism involves CHAC2-mediated reduction of GSH, leading to elevated ROS and MAPK pathway activation.
• CHAC2 represents a potential novel therapeutic target for lung adenocarcinoma treatment.